ATHE News and Press, Alterity Therapeutics Limited From 12/04/23

2023-12-04 12:22:42 ET DENVER, Colo., Dec. 4, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; SilverSun Technologies Inc (NASDAQ: SSNT), EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), Alterity Therap...

2023-12-04 10:02:05 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble For further details see: Ocular Therapeutix, EyePoint Pharmaceuticals among healthcare movers

2023-12-04 10:01:55 ET DENVER, Colo., Dec. 4, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), SilverSun Technologies Inc (NASDAQ: SSNT), Alterity Therapeutics ...

2023-12-04 07:46:49 ET Alterity Therapeutics ( NASDAQ: ATHE ) shares rallied on Monday after the biotech firm reported positive efficacy data for its lead asset, ATH434, in a Parkinson's disease primate model. ATH434 has the potential to treat various Parkinsonian disorders ...

- ATH434 improved motor performance and general function – - Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Al...

2023-11-27 10:50:10 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...

2023-11-22 12:41:46 ET More on Mid-day movers stock. BioVie: Upcoming Phase 3 Readout In Alzheimer's May Create Significant Value BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade) BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly B...

2023-11-22 10:00:14 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...